Bipolar Disorder Market is estimated to be US$ 6.7 billion by 2030 with a CAGR of 2.3%

Author: Siju Thomas

The Bipolar Disorder Market accounted for US$ 5.3 billion in 2020 and is estimated to be US$ 6.7 billion by 2030 and is anticipated to register a CAGR of 2.3%. Bipolar disorder known as manic depression is a mental illness that brings low moods and severe high moods, thinking, changes in sleep and have periods in which they feel overly happy and energized and other side feel very sad, hopeless and sluggish. Bipolar disorder can cause severe disruption to a person’s life which can be treated with appropriate treatment and support.

The report " Global Bipolar Disorder Market, By Disorder (Bipolar I Disorder, Bipolar II Disorder, Cyclothymic Disorder), By Drug Class (Mood Stabilizer, Anticonvulsant, Antipsychotic Drugs, Antidepressant Drugs, and Antianxiety Drugs), By Mechanism of Action (Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Tricyclic Antidepressants, Beta Blockers, and Benzodiazepines), By Region (North America, Europe, Asia Pacific, Latin America and Middle East & Africa) – Trends, Analysis and Forecast till 2030"

Key Highlights:

  • Sept. 18, 2015, new antipsychotic drug (Cariprazine) to treat schizophrenia and bipolar disorder in adults has been approved by the U.S. Food and Drug Administration.

Analyst View:

Increasing prevalence of bipolar disorder drives the market. Government support for spreading awareness and technological advancements that facilitate accurate detection of patient’s mood & mental state drives the market. Antipsychotic drug dominated the market as these drugs overcome the limitations faced by traditional antidepressants as they stabilize the mood.

Before purchasing this report, request a sample or make an inquiry by clicking the following link:

https://www.prophecymarketinsights.com/market_insight/Global-Bipolar-Disorder-Market-By-1016

Key Market Insights from the report:

The Global Bipolar Disorder Market accounted for US$ 5.3 billion in 2020 and is estimated to be US$ 6.7 billion by 2030 and is anticipated to register a CAGR of 2.3%. The Global Bipolar Disorder Market is segmented based on the disorder, drug class, mechanism of action, and region.

  • By Disorder, the Global Bipolar Disorder Market is segmented into Bipolar I Disorder, Bipolar II Disorder, Cyclothymic Disorder.
  • By Drug Class, the market is segmented Mood Stabilizer, Anticonvulsant, Antipsychotic Drugs, Antidepressant Drugs, and Antianxiety Drugs.
  • By Mechanism of Action, the Global Bipolar Disorder Market is segmented into Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Tricyclic Antidepressants, Beta Blockers, and Benzodiazepines
  • By region, the Global Bipolar Disorder Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Competitive Landscape:

The market key players in the global bipolar disorder market are AstraZeneca limited., Pfizer Inc., Glaxo SmithKline (GSK) Pvt Lt., Eli Lilly Inc., Janssen Pharmaceuticals, Novartis AG pharmaceutical limited, Allergan Plc., Otsuka Holdings Co. Ltd., and AbbVie Inc.

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.